Carlyle to Buy Drugmaker Vectura for $1.4 Billion in Cash
- Private equity offer is 27% above Vectura’s close Tuesday
- Vectura’s board endorses deal seen closing in third quarter
This article is for subscribers only.
Carlyle Group Inc. agreed to buy Vectura Group Plc for about 958 million pounds ($1.4 billion) in cash to boost the U.K. drugmaker’s transformation.
The private equity firm offered 136 pence in cash as well as a 19-pence cash dividend for each Vectura share held, the companies said in a statement. The offer represents a 27% premium to Vectura’s Tuesday closing price. The stock surged as much as 31% in London trading Wednesday.